Search results
TBL1 Suppresses Cardiomyocyte Hypertrophy by Regulating the Interaction Between HDAC3 and GATA4
Author(s):
Yasufumi Katanasaka
,
Masatoshi Namiki
,
Yoichi Sunagawa
,
et al
Added:
3 years ago
Article
Author(s):
Astrid Hubert
,
Andreas Seitz
,
Valeria Martínez Pereyra
,
et al
Added:
3 years ago
Coronary artery spasm (CAS) is an established cause for anginal chest pain, the cardinal symptom of myocardial ischaemia, in patients with angiographically unobstructed coronary arteries. Evidence from large clinical studies has revealed that about 50% of patients undergoing diagnostic coronary angiography for suspected coronary artery disease (CAD) had either normal or near normal coronary…
View more
Author(s):
Mariëlle GJ Duffels
,
Eric Boersma
,
Barbara JM Mulder
Added:
3 years ago
Congenital heart disease is the most common congenital malformation and accounts for about eight cases per 1,000 births.1 Due to tremendous developments in cardiac surgery, nearly 90% of all children with congenital heart disease reach adult age. In patients with congenital heart disease, pulmonary arterial hypertension (PAH) may develop due to increased pulmonary arterial flow as a result of a…
View more
Author(s):
Jean-Luc Vachiéry
Added:
3 years ago
Prostacyclins in PAH - Pathobiological Rationale
Endothelial dysfunction is the cornerstone event in the pathobiology of pulmonary arterial hypertension (PAH), a rapidly evolving clinical syndrome of dyspnoea and fatigue eventually leading to right ventricular failure and death.1 In the pulmonary vascular bed, endothelial cells are the major source of mediators modulating pulmonary vascular tone…
View more
Author(s):
Robert Voswinckel
,
Ralph T Schermuly
,
Norbert Weissmann
,
et al
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a chronic, progressive disease defined by increasing pulmonary vascular resistance and pulmonary arterial pressure, ultimately leading to right heart failure. The life expectancy of patients with PAH who do not receive appropriate treatment is dramatically reduced. Guidelines for the diagnosis and treatment of PAH have been established by the American…
View more
Author(s):
Wouter Jacobs
,
Anton Vonk-Noordegraaf
Added:
3 years ago
Abstract
Pulmonary arterial hypertension is a progressive disease of the pulmonary vasculature, ultimately leading to right heart failure and death. Current treatment is aimed at targeting three different pathways: the prostacyclin, endothelin and nitric oxide pathways. These therapies improve functional class, increase exercise capacity and improve haemodynamics. In addition, data from a meta…
View more
Author(s):
Maria Teresa Bayo Jimenez
,
Omar Hahad
,
Marin Kuntic
,
et al
Added:
11 months ago
Author(s):
Claudio Borghi
,
Arrigo FG Cicero
Added:
3 years ago
It is well known that hypertension is a strong independent risk factor for coronary and cerebrovascular diseases, as well as for heart failure, atrial fibrillation and chronic renal failure, in both industrialised and developing countries,1 thus substantially contributing to the global burden of disease. Moreover, it is well known that reducing blood pressure (BP) in hypertensive patients is…
View more
Author(s):
Hossein-Ardeschir Ghofrani
,
Ralph Schermuly
,
Norbert Weissmann
,
et al
Added:
3 years ago
Pulmonary arterial hypertension (PAH) has an estimated prevalence of 15–25 cases/million population.1 This chronic, progressive disease is defined by a mean pulmonary arterial pressure >25mmHg in conjunction with normal pulmonary capillary wedge pressure <15mmHg.2 The disease is characterized by increased vascular resistance of the pulmonary microvasculature, ultimately resulting in right…
View more
Author(s):
Carmine Dario Vizza
,
Roberto Badagliacca
,
Roberto Poscia
,
et al
Added:
3 years ago
Abstract
Pulmonary arterial hypertension (PAH) is a serious and life-threatening condition for which the prognosis remains poor. Treatment options include endothelial receptor antagonists, phosphodiesterase (PDE5) inhibitors and prostanoids. Despite all demonstrating good short-term efficacy, none of the currently available drug therapies are curative. Treatment with prostanoids is complex and…
View more